Preview of Proteus Report. Akili gets FDA OK (finally).

Issue 057.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Haven's health coaching partner going public. Next week I am open to ideas -- what should E&O dig into? Here's what's happening this week:

What a busy week. I pulled together The Proteus Digital Health Report after the long-running company filed for Chapter 11 bankruptcy on Monday. There's a bit more on that report below or just head to E&O to read the full 4,400-word report now.
The other big news this week: On Monday the FDA announced that it had (finally) granted Akili Interactive a De Novo clearance for EndeavorRx (AKL-T01), which is video game-based prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD). Perhaps the most remarkable thing about this move by the FDA is that its database shows it only took TWO MONTHS from the time

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Preview of Proteus Report. Akili gets FDA OK (finally).

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.